Skip to main content
    • Mounjaro

    Can Mounjaro Cause Cancer? What the UK Product Information Says

    Can Mounjaro cause cancer? A UK pharmacist on what its product information says about thyroid tumours in rats, pancreatic cancer and who should avoid it.

    Jimah Alsaai MPharmJimah Alsaai MPharmSuperintendent Pharmacist
    GPhC 2232652
    Reviewed November 2026
    9 min read

    Start your free consultation with a GPhC-registered pharmacist.

    Begin consultation

    Short answer: Mounjaro (tirzepatide) does not list cancer as a side effect in its UK product information, and its warnings section has no cancer warning (SmPC, sections 4.4 and 4.8). The question comes from animal studies: in rats given tirzepatide for 2 years, thyroid C-cell tumours increased at every dose, and the product information says the human relevance of this is unknown (section 5.3).

    The MHRA has issued no safety update on GLP-1 medicines and cancer, and Cancer Research UK says it is too early to understand their full impact. We do not supply Mounjaro if you or a blood relative have had medullary thyroid cancer or MEN2.

    This guide sets out what the UK product information, the MHRA, the NHS and two UK cancer charities say, as of November 2026: thyroid cancer, pancreatic cancer and pancreatitis, what the trials have found, cancer treatment, and who we do not supply.

    Can Mounjaro cause cancer?

    Nothing in the UK product information says Mounjaro causes cancer in people, and nothing says it cannot. Cancer is not among the side effects it lists, and its only contraindication is an allergy to tirzepatide or its ingredients.

    The one cancer finding is in the animal studies, and it concerns the thyroid. The table shows what each source says, and when it was last revised.

    SourceWhat it says about cancer
    Mounjaro product information, section 4.3 (contraindications), 29 Aug 2026One contraindication: an allergy to tirzepatide or any ingredient. No cancer is named
    Section 4.4 (warnings and precautions)Warns about acute pancreatitis, low blood sugar, dehydration and other effects. No warning about cancer or the thyroid
    Section 4.8 (side effects)No cancer listed. A raised level of calcitonin in the blood is listed as common in the weight management trials
    Section 5.3 (animal studies), ratsA 2-year study: more thyroid C-cell tumours, benign and cancerous, at all doses. "The human relevance of these findings is unknown"
    Section 5.3, miceA 6-month cancer study in a specially bred type of mouse: no increase in thyroid C-cell growths at any dose
    Mounjaro patient leaflet, August 2026No cancer listed. Inflamed pancreas (acute pancreatitis) is listed as uncommon, up to 1 in 100 people
    MHRA guidance on GLP-1 medicines, updated 5 Feb 2026, and its Drug Safety UpdatesNo mention of cancer. Its safety advice covers pancreatitis, fake medicines, pregnancy, operations and eyesight
    NHS tirzepatide page, reviewed 15 May 2026No cancer among its side effects or the people it may not suit
    US prescribing information, September 2026A boxed warning about thyroid C-cell tumours in rats. Not to be used with a personal or family history of medullary thyroid cancer or MEN 2

    For everything else the product information covers, read our guide to whether Mounjaro is safe, and our list of Mounjaro side effects.

    Can Mounjaro cause thyroid cancer?

    It is not known. In a 2-year study, rats given tirzepatide twice a week developed more thyroid C-cell tumours than untreated rats, at every dose tested. The doses gave from about a tenth of the exposure of the highest human dose up to about the same.

    The product information says the human relevance of this is unknown. In a 6-month cancer study in a specially bred type of mouse, there was no increase.

    The US prescribing information names medullary thyroid cancer, which Macmillan Cancer Support calls a rare type of thyroid cancer, among the C-cell tumours it is unknown whether Mounjaro causes in people. The NHS describes thyroid cancer in general as quite rare in the UK.

    Why is calcitonin mentioned?

    A raised level of calcitonin in the blood is listed as a common finding in the weight management trials. The product information lists it among its test results and gives no further advice about it.

    What should you look out for?

    The approved advice we give everyone on a GLP-1 medicine includes the neck:

    Seek advice promptly if you notice: signs of dehydration during vomiting or diarrhoea (dizziness, reduced urination, dry mouth): keep sipping fluids, as dehydration can affect your kidneys; palpitations or a racing heartbeat at rest; a new neck lump, swelling, or hoarseness. If you have type 2 diabetes and use insulin or a sulfonylurea, know the signs of low blood sugar (sweating, shaking, sudden hunger, confusion) and treat promptly.

    Why does Mounjaro have a thyroid cancer warning in the US?

    In the US, Mounjaro's prescribing information carries a boxed warning about the rat findings. It says it is unknown whether Mounjaro causes thyroid C-cell tumours, including medullary thyroid cancer, in people.

    The US information also says Mounjaro must not be used by anyone with a personal or family history of medullary thyroid cancer or with MEN 2, and asks prescribers to tell patients the symptoms of a thyroid tumour.

    The UK product information has no such warning: it reports the rat finding in its animal studies section and lists one contraindication, an allergy. Our service has its own rule: we do not supply Mounjaro if you or a blood relative have had medullary thyroid cancer or MEN2.

    The same animal finding is described for other GLP-1 medicines too. The UK product information for Wegovy calls these rodent tumours "a class effect for GLP-1 receptor agonists".

    Who should not take Mounjaro because of cancer?

    We do not supply Mounjaro if you or a blood relative have had medullary thyroid cancer (MTC) or multiple endocrine neoplasia type 2 (MEN2). Our consultation also asks whether you are having cancer treatment now.

    • Medullary thyroid cancer or MEN2, in you or a blood relative. We do not supply Mounjaro. Other thyroid cancers, such as papillary or follicular, are not this question: the consultation asks you to tell us about them instead, and the pharmacist reviews your answer.
    • Chemotherapy, immunotherapy or other active cancer treatment. The consultation asks about this, and that answer can mean we cannot supply Mounjaro. If you have finished treatment and only have check-ups, the consultation asks you to tell us that.

    Wondering whether Mounjaro suits you? Our consultation asks about your health and the medicines you take, and a GPhC-registered pharmacist reviews every answer before anything is supplied.

    Check your eligibility

    Can Mounjaro cause pancreatic cancer?

    Pancreatic cancer is not listed as a side effect in the UK product information. What it does warn about is acute pancreatitis, an inflamed pancreas, which is a different condition.

    Acute pancreatitis is uncommon, affecting up to 1 in 100 people, and there have been rare reports of severe and fatal cases. In January 2026 the MHRA strengthened the warnings about it for GLP-1 medicines, tirzepatide included. We do not supply Mounjaro to anyone who has had pancreatitis.

    Stop your treatment and seek urgent medical help if you experience: severe, persistent stomach pain, especially spreading to your back, with or without vomiting. This can be a sign of pancreatitis. Sudden pain in the upper right of your tummy, fever, or yellowing of the skin or eyes: possible gallbladder problems. Sudden loss of vision, or loss of part of your field of vision: seek same-day eye assessment. Swelling of the face or lips, difficulty breathing, or a widespread rash: call 999.

    Blood tests can show raised pancreatic enzymes (lipase and amylase) on Mounjaro. The product information says a raised level on its own does not predict pancreatitis, and its meaning is unknown without other signs. Our guide to Mounjaro and gallstones covers the other cause of severe tummy pain to know about.

    What have studies found about Mounjaro and cancer?

    The trials so far have not shown a clear difference in cancer between people on these medicines and people on placebo. They were short, though, and not designed to look for cancer.

    A 2026 review in the Annals of Internal Medicine pooled 48 randomised trials of GLP-1 medicines, tirzepatide among them, with 94,245 people. The chart shows the four cancers its summary gives figures for.

    GLP-1 medicines and four cancers: what 48 trials foundEach row is one type of cancer. The figure compares the odds of that cancer on the medicine with the odds on placebo: 1 means the same. The line through each dot is the range the true figure is likely to lie in.
    The trials found more cases with the medicineThe trials could not tell the groups apart
    48 randomised trials of GLP-1 medicines, tirzepatide included
    • Thyroid cancer1.37 (0.82 to 2.31)
      Medicine against placebo.
    • Pancreatic cancer0.84 (0.53 to 1.35)
      Medicine against placebo.
    • Breast cancer0.95 (0.60 to 1.49)
      Medicine against placebo.
    • Kidney cancer1.12 (0.78 to 1.60)
      Medicine against placebo.
    Odds ratios with 95% confidence intervals, from Ko and colleagues, Annals of Internal Medicine, 2026 (48 randomised trials, 94,245 people), as its abstract on PubMed reports them. The authors rate the certainty as moderate, note the trials were not designed to look for cancer and had short follow-up, and say longer-term studies are needed.

    The authors concluded that these medicines probably have little or no effect on thyroid, pancreatic, breast or kidney cancer. Every range in the chart crosses 1, and the thyroid range runs up to more than double the odds, so a small increase or decrease cannot be ruled out.

    A 2025 review of 13 trials of tirzepatide alone (13,761 people, 26 to 72 weeks) found that tirzepatide did not increase the risk of any cancer, or of any specific type, against the comparison groups. Like the 2026 review, it can speak only for the length of those trials.

    Can weight loss on Mounjaro lower your cancer risk?

    That has not been shown. Cancer Research UK says overweight and obesity is the biggest cause of cancer in the UK after smoking, but that it has not been proven that these medicines reduce cancer risk.

    Macmillan Cancer Support says the same: there is no clear evidence that weight-loss injections reduce the risk of cancer. Mounjaro is licensed for weight management, not to prevent cancer.

    Can you take Mounjaro during cancer treatment?

    Speak to your cancer team first. Macmillan advises always talking to your cancer team before starting or continuing weight-loss injections.

    • During treatment, keeping your strength, muscle and energy is usually more important than losing weight.
    • Mounjaro slows stomach emptying, which can change how medicines taken by mouth are absorbed. Macmillan names oral chemotherapy among them.
    • If you are losing weight without meaning to, tell your healthcare team.

    Is Ozempic or Mounjaro safer?

    They are different medicines, tested in different trials, so the product information does not answer that. Ozempic is semaglutide, which in the UK is used for type 2 diabetes; Mounjaro is tirzepatide.

    The UK product information for each reports thyroid C-cell tumours in rodent studies, and each words its view of what that means for people differently. Neither document compares itself with the other, and which medicine suits you depends on your health. Our guides to Mounjaro and Ozempic and to whether Wegovy is safe set out each one.

    How do you report a side effect?

    Report a suspected side effect on the MHRA Yellow Card website or app, and tell us too, so your pharmacist can review your treatment. Mounjaro is under additional monitoring, so every report adds to what is known. You can read more about our checks on the safety page, and about treatment options on our weight loss page.

    Switching from another provider?

    You may be able to carry on at your current dose. Upload proof of your current treatment during your consultation, and your pharmacist checks it before anything is supplied.

    When should you speak to your pharmacist or doctor?

    Stop your treatment and seek urgent medical help if you experience: severe, persistent stomach pain, especially spreading to your back, with or without vomiting. This can be a sign of pancreatitis. Sudden pain in the upper right of your tummy, fever, or yellowing of the skin or eyes: possible gallbladder problems. Sudden loss of vision, or loss of part of your field of vision: seek same-day eye assessment. Swelling of the face or lips, difficulty breathing, or a widespread rash: call 999.

    Seek advice promptly if you notice: signs of dehydration during vomiting or diarrhoea (dizziness, reduced urination, dry mouth): keep sipping fluids, as dehydration can affect your kidneys; palpitations or a racing heartbeat at rest; a new neck lump, swelling, or hoarseness. If you have type 2 diabetes and use insulin or a sulfonylurea, know the signs of low blood sugar (sweating, shaking, sudden hunger, confusion) and treat promptly.

    Before any operation: tell your surgical or anaesthetic team you take a GLP-1 medicine. It slows stomach emptying, which matters for anaesthesia.

    If you are diagnosed with cancer while taking Mounjaro, or start cancer treatment, tell your cancer team and message your pharmacist before your next dose.

    For urgent medical concerns, call NHS 111 or 999.

    Urgent help, genuine medicines and the official leaflets

    Frequently asked questions

    Cancer is not listed as a side effect in the UK product information for Mounjaro (tirzepatide), and its warnings section has no cancer warning. In a 2-year study in rats, tirzepatide caused thyroid C-cell tumours at every dose tested, and the product information says the human relevance of this is unknown. The MHRA has issued no safety update on GLP-1 medicines and cancer, and Cancer Research UK says it is too early to understand their full impact on cancer.

    In a 2-year study in rats, tirzepatide caused thyroid C-cell tumours, both benign and cancerous, at all doses compared with untreated rats. The UK product information says the human relevance of this is unknown, and a 6-month study in a type of mouse found no increase. Thyroid cancer is not listed as a side effect in people. We do not supply Mounjaro if you or a blood relative have had medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN2).

    The UK product information does not list thyroid cancer as a side effect, and it is not known whether tirzepatide causes thyroid tumours in people. A 2026 review of 48 randomised trials of GLP-1 medicines found they probably have little or no effect on thyroid cancer, with moderate certainty, but a small increase could not be ruled out, and the trials were not designed to look for cancer and were short. If you notice a new lump or swelling in your neck, or hoarseness, speak to your pharmacist or GP.

    The US prescribing information for Mounjaro carries a boxed warning about the thyroid C-cell tumours seen in rats, says it is unknown whether Mounjaro causes them in people, and says it must not be used by anyone with a personal or family history of medullary thyroid cancer or with MEN 2. The UK product information has no such warning: it reports the rat finding in its animal studies section and lists one contraindication, an allergy to tirzepatide or its ingredients. We do not supply Mounjaro if you or a blood relative have had medullary thyroid cancer or MEN2.

    Pancreatic cancer is not listed as a side effect in the UK product information for Mounjaro. What it does warn about is acute pancreatitis, an inflamed pancreas, which is uncommon (up to 1 in 100 people) and can be serious. A 2026 review of 48 randomised trials found GLP-1 medicines probably have little or no effect on pancreatic cancer, but a small increase could not be ruled out, and the trials were short and not designed to look for cancer. Severe, persistent stomach pain, especially spreading to your back, needs urgent medical help.

    Breast cancer is not listed as a side effect in the UK product information for Mounjaro. A 2026 review of 48 randomised trials of GLP-1 medicines found they probably have little or no effect on the risk of breast cancer, with moderate certainty, though a small increase could not be ruled out. Its authors say the trials were not designed to look for cancer, had short follow-up, and that longer-term studies are needed.

    Speak to your cancer team first. Macmillan Cancer Support advises always talking to your cancer team before starting or continuing weight-loss injections, because keeping your strength and muscle is usually more important than losing weight during treatment, and the slower stomach emptying can affect medicines taken by mouth, including oral chemotherapy. Our consultation asks whether you are having chemotherapy, immunotherapy or other active cancer treatment, and that answer can mean we cannot supply Mounjaro.

    The UK product information for Mounjaro does not list an underactive thyroid (hypothyroidism) among its warnings or side effects, and it is a different condition from thyroid cancer. It does say Mounjaro slows stomach emptying, which can affect how other medicines taken by mouth are absorbed, most of all when you start. Our consultation asks about every medicine you take, and the pharmacist reviews your answers before anything is supplied.

    They are different medicines: Ozempic is semaglutide, which in the UK is used for type 2 diabetes, and Mounjaro is tirzepatide. Each was tested in its own trials, and the UK product information for each reports thyroid C-cell tumours in rodent studies. Neither document compares itself with the other, so the product information does not show that one is safer. Which medicine suits you depends on your health, and a prescriber decides.

    Keep reading

    Sources · 14Show
    1. Mounjaro KwikPen Summary of Product Characteristics, sections 4.3, 4.4, 4.5, 4.8 and 5.3, electronic medicines compendium. Text revised 29 August 2026.
    2. Mounjaro KwikPen patient information leaflet, sections 2 and 4, electronic medicines compendium. Last revised August 2026.
    3. Ozempic Summary of Product Characteristics, sections 4.1 and 5.3, electronic medicines compendium. Revised July 2026.
    4. Wegovy FlexTouch Summary of Product Characteristics, section 5.3, electronic medicines compendium. Revised September 2026.
    5. MHRA, GLP-1 medicines for weight loss and diabetes: what you need to know. Updated 5 February 2026.
    6. MHRA Drug Safety Update, GLP-1 and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases. 29 January 2026.
    7. NHS, Tirzepatide. Page last reviewed 15 May 2026.
    8. NHS, What is thyroid cancer? Page last reviewed 14 October 2026.
    9. Mounjaro (tirzepatide) US prescribing information, boxed warning and section 5.1, Eli Lilly and Company, DailyMed. Published 2 September 2026.
    10. Cancer Research UK, Weight loss drugs and cancer: what we know so far. 5 February 2026.
    11. Macmillan Cancer Support, Weight-loss injections and cancer: your questions answered. 24 February 2026.
    12. Ko A, et al. Risk for cancer with glucagon-like peptide-1 receptor agonists and dual agonists: a systematic review and meta-analysis. Annals of Internal Medicine, 2026;179(2):216-229. PMID 41359966.
    13. Kamrul-Hasan ABM, et al. Tirzepatide and cancer risk in individuals with and without diabetes: a systematic review and meta-analysis. Endocrinology and Metabolism, 2025;40(1):112-124. PMID 39814031.
    14. MHRA Yellow Card scheme.

    Reviewed by Jimah Alsaai MPharm, GPhC 2232652, Superintendent Pharmacist, QuickCare Pharmacy.

    Ready to start?

    Start your free consultation with a GPhC-registered pharmacist.

    Begin consultation

    Follow us on Instagram (opens Instagram in a new tab)